Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
NICE suggests bortezomib, thalidomide for multiple myeloma patients

NICE suggests bortezomib, thalidomide for multiple myeloma patients

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Aging thalidomide victims to receive $50 million in compensation

Aging thalidomide victims to receive $50 million in compensation

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Japan's MHLW grants full marketing authorization to REVLIMID

Japan's MHLW grants full marketing authorization to REVLIMID

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene reports initial data from investigator-initiated study of REVLIMID

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

Researchers present clinical outcomes of lenalidomide in patients with large B-cell lymphoma

US District Court dismisses all claims and counterclaims in thalidomide patent cases

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Rebirth of the cursed drug Thalidomide

Rebirth of the cursed drug Thalidomide

New report assesses optimal future for REMS

New report assesses optimal future for REMS

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene reports total revenue of $758M for fourth-quarter of 2009